The new malaria vaccine is a total game changer

Abstract

A new malaria vaccine, R21/MM, has demonstrated 77% efficacy in a phase 2 clinical trial conducted in Burkina Faso. This represents a significant improvement over the efficacy of the currently available malaria vaccine, RTS,S, which has an efficacy of around 55%. R21/MM targets a specific protein on the surface of the Plasmodium parasite in its sporozoite form, and utilizes an adjuvant, Matrix-M, to enhance the immune response. The vaccine is administered with three shots followed by a booster shot one year later. While phase 3 trials are underway to further evaluate the vaccine’s safety and efficacy, the results of the phase 2 trial are promising and suggest that R21/MM could significantly reduce malaria deaths, particularly among young children and pregnant women in malaria-affected regions. – AI-generated abstract.